Maria RosÃ¡rio Almeida

List of Publications by Year
in descending order

52 papers	1,879 citations	218677 26 h-index	265206 42 g-index
54 all docs	54 docs citations	54 times ranked	1821 citing authors

#	Article	IF	Citations
1	Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 2016, 7, 10787.	12.8	139
2	Natural polyphenols inhibit different steps of the process of transthyretin (TTR) amyloid fibril formation. FEBS Letters, 2011, 585, 2424-2430.	2.8	133
3	Binding of epigallocatechinâ€3â€gallate to transthyretin modulates its amyloidogenicity. FEBS Letters, 2009, 583, 3569-3576.	2.8	122
4	Epigallocatechin-3-Gallate as a Potential Therapeutic Drug for TTR-Related Amyloidosis: â€œIn Vivoâ€• Evidence from FAP Mice Models. PLoS ONE, 2012, 7, e29933.	2.5	94
5	Thyroxine binding to transthyretin Met 119. Endocrine, 1997, 6, 309-315.	2.3	90
6	Selective binding to transthyretin and tetramer stabilization in serum from patients with familial amyloidotic polyneuropathy by an iodinated diflunisal derivative. Biochemical Journal, 2004, 381, 351-356.	3.7	88
7	Comparative Studies of Two Transthyretin Variants with Protective Effects on Familial Amyloidotic Polyneuropathy: TTR R104H and TTR T119M. Biochemical and Biophysical Research Communications, 2000, 270, 1024-1028.	2.1	61
8	Anti-apoptotic treatment reduces transthyretin deposition in a transgenic mouse model of Familial Amyloidotic Polyneuropathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 517-522.	3.8	57
9	Small Transthyretin (TTR) Ligands as Possible Therapeutic Agents in TTR Amyloidoses. CNS and Neurological Disorders, 2005, 4, 587-596.	4.3	54
10	Transthyretin Deposition in Familial Amyloidotic Polyneuropathy. Current Medicinal Chemistry, 2012, 19, 2304-2311.	2.4	52
11	Iodine Atoms: A New Molecular Feature for the Design of Potent Transthyretin Fibrillogenesis Inhibitors. PLoS ONE, 2009, 4, e4124.	2.5	51
12	Substrate specificity of transthyretin: identification of natural substrates in the nervous system. Biochemical Journal, 2009, 419, 467-474.	3.7	45
13	Two transthyretin variants (TTR Ala-49 and TTR Gln-89) in two sicilian kindreds with hereditary amyloidosis. Human Mutation, 1992, 1, 211-215.	2.5	44
14	Isatin derivatives, a novel class of transthyretin fibrillogenesis inhibitors. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5270-5273.	2.2	44
15	Dietary curcumin counteracts extracellular transthyretin deposition: Insights on the mechanism of amyloid inhibition. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2013, 1832, 39-45.	3.8	43
16	Screening and biochemical characterization of transthyretin variants in the Portuguese population. Human Mutation, 1997, 9, 226-233.	2.5	41
17	Molecular Tweezers Targeting Transthyretin Amyloidosis. Neurotherapeutics, 2014, 11, 450-461.	4.4	41
18	Transthyretin Leu 68 in a form of cardiac amyloidosis. Basic Research in Cardiology, 1991, 86, 567-571.	5.9	39

#	Article	IF	Citations
19	Interaction with human plasminogen system turns on proteolytic activity in Streptococcus agalactiae and enhances its virulence in a mouse model. Microbes and Infection, 2007, 9, 1276-1284.	1.9	39
20	Functional characterization of Arabidopsis thaliana transthyretin-like protein. BMC Plant Biology, 2010, 10, 30.	3.6	39
21	Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 2016, 6, 26623.	3.3	38
22	Transthyretin Interacts with Metallothionein 2. Biochemistry, 2008, 47, 2244-2251.	2.5	34
23	Prenatal diagnosis of familial amyloidotic polyneuropathy: evidence for an early expression of the associated transthyretin methionine 30. Human Genetics, 1990, 85, 623-6.	3.8	33
24	The binding of xanthone derivatives to transthyretin. Biochemical Pharmacology, 2005, 70, 1861-1869.	4.4	30
25	Comparative in vitro and ex vivo activities of selected inhibitors of transthyretin aggregation: relevance in drug design. Biochemical Journal, 2007, 408, 131-138.	3.7	30
26	Uncovering the Neuroprotective Mechanisms of Curcumin on Transthyretin Amyloidosis. International Journal of Molecular Sciences, 2019, 20, 1287.	4.1	28
27	Natural polyphenols as modulators of TTR amyloidogenesis: in vitro and in vivo evidences towards therapy. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 39-42.	3.0	26
28	Human metallothioneins 2 and 3 differentially affect amyloidâ€beta binding by transthyretin. FEBS Journal, 2010, 277, 3427-3436.	4.7	25
29	Clearance of extracellular misfolded proteins in systemic amyloidosis: Experience with transthyretin. FEBS Letters, 2012, 586, 2891-2896.	2.8	25
30	Modulation of the Mechanisms Driving Transthyretin Amyloidosis. Frontiers in Molecular Neuroscience, 2020, 13, 592644.	2.9	24
31	Choroid Plexus in Alzheimerâ€™s Diseaseâ€”The Current State of Knowledge. Biomedicines, 2022, 10, 224.	3.2	23
32	Haplotype analysis of common transthyretin mutations. Human Genetics, 1995, 96, 350-4.	3.8	21
33	Transthyretin chemical chaperoning by flavonoids: Structureâ€“activity insights towards the design of potent amyloidosis inhibitors. Biochemistry and Biophysics Reports, 2015, 3, 123-133.	1.3	20
34	TTR exon scanning in peripheral neuropathies. Neuromuscular Disorders, 1995, 5, 187-191.	0.6	18
35	Thyroxine binding to transthyretin (TTR) variantsâ€”two variants (TTR Pro 55 and TTR Met 111) with a particularly low binding affinity. European Journal of Endocrinology, 1996, 135, 226-230.	3.7	17
36	A novel bis-furan scaffold for transthyretin stabilization and amyloid inhibition. European Journal of Medicinal Chemistry, 2016, 121, 823-840.	5.5	17

#	Article	IF	Citations
37	Characterization of a basic transthyretin variant - TTR Arg 102 - in the German population. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1991, 1097, 224-226.	3.8	16
38	Transthyretin ALA 71: A new transthyretin variant in a Spanish family with familial amyloidotic polyneuropathy. Human Mutation, 1993, 2, 420-421.	2.5	16
39	Iodination of salicylic acid improves its binding to transthyretin. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2008, 1784, 512-517.	2.3	16
40	Tuning Transthyretin Amyloidosis Inhibition Properties of Iododiflunisal by Combinatorial Engineering of the Nonsalicylic Ring Substitutions. ACS Combinatorial Science, 2015, 17, 32-38.	3.8	16
41	Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation. Scientific Reports, 2017, 7, 44709.	3.3	16
42	Unusual Self-Association Properties of Transthyretin Y114C Related to Familial Amyloidotic Polyneuropathy: Effects on Detection and Quantification. Biochemical and Biophysical Research Communications, 1999, 261, 264-269.	2.1	14
43	Familial amyloidotic polyneuropathy: transthyretin (prealbumin) variants in kindreds of Italian origin. Human Genetics, 1988, 80, 341-343.	3.8	12
44	Impairment of autophagy by TTR V30M aggregates: inÂvivo reversal by TUDCA and curcumin. Clinical Science, 2016, 130, 1665-1675.	4.3	11
45	Gene therapy approach to FAP: in vivo influence of T119M in TTR deposition in a transgenic V30M mouse model. Gene Therapy, 2014, 21, 1041-1050.	4.5	10
46	Amyloidogenic and nonâ€amyloidogenic transthyretin Asn 90 variants. Clinical Genetics, 1992, 42, 27-30.	2.0	8
47	SERPINA1 modulates expression of amyloidogenic transthyretin. Experimental Cell Research, 2020, 395, 112217.	2.6	7
48	In Vitro and In Vivo Effects of SerpinA1 on the Modulation of Transthyretin Proteolysis. International Journal of Molecular Sciences, 2021, 22, 9488.	4.1	7
49	Targeting transthyretin amyloidosis in the eye with next-generation stabilizers: AT40 displays potent TTR stabilization in the human vitreous. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 73-74.	3.0	2
50	TTR Leu 64 in an FAP kindred identified by PCR-RFLP analysis. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 1994, 1, 184-185.	3.0	1
51	Lead optimization of resilient next-generation transthyretin stabilizers for multiple target-product profiles: approaching the CNS. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2019, 26, 77-78.	3.0	1
52	In Vitro and in Vivo Effects of Genistein on Ttr Stabilization and Aggregation. , 2007, , 113-115.		0